5-Fluorouracil derivatives: A patent review

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 2, 2012, Pages 107-123

  Lvarez, Pablo ^a   Marchal, Juan Antonio ^a,b   Boulaiz, Houria ^a,b   Carrillo, Esmeralda ^a,b   Vélez, Celia ^a,b   Rodrguez Serrano, Fernando ^a,b   Melguizo, Consolacin ^a,b   Prados, Jose ^a,b   Madeddu, Roberto ^c   Aranega, Antonia ^a,b  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSITY OF SASSARI   (Italy)

Author keywords

5 fluorouracil; Nanomedicine; O,N acetals; Oral prodrugs; Solid tumors; Targeted therapy

Indexed keywords

5 ETHYNYLURACIL; ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DIHYDROFLUOROURACIL; DNA; DOCETAXEL; DOXIFLURIDINE; FLUOROPYRIMIDINE; FLUOROURACIL; FLUOROURACIL DERIVATIVE; FOLINIC ACID; GEMCITABINE; GIMERACIL; IRINOTECAN; LIPOSOME; MESSENGER RNA; MICROSPHERE; NANOPARTICLE; ORZEL; OTERACIL POTASSIUM; OXALIPLATIN; PACLITAXEL; POLYSACCHARIDE FLUOROURACIL; RIBONUCLEOTIDE REDUCTASE; TEGAFUR; UFT; UNCLASSIFIED DRUG; VORINOSTAT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; COLON CANCER; COLORECTAL CANCER; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG COST; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; HALF LIFE TIME; HUMAN; IC 50; IN VIVO STUDY; LUNG NON SMALL CELL CANCER; MOLECULAR WEIGHT; NONHUMAN; PANCREAS CANCER; RECTUM CANCER; REVIEW; RNA TRANSLATION; STOMACH CANCER; TUMOR XENOGRAFT; VIRUS;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; DRUG DESIGN; FLUOROURACIL; HUMANS; LEGISLATION, DRUG; MOLECULAR STRUCTURE; PATENTS AS TOPIC; PHARMACOGENETICS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84857546085     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.661413     Document Type: Review

References (136)

1. Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 1957;179:663-6
2. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol 2004;22:2214-32
3. Marchal JA, Boulaiz H, Rodriguez-Serrano F, et al. 5-fluorouracil derivatives induce differentiation mediated by tubulin and HLA class I modulation. Med Chem 2007;3:233-9
4. Ozaki S, Watanabe Y, Hoshiko T, et al. 5-Fluorouracil derivatives (IV): synthesis of antitumor active acyloxyalkyl-5-fluouracils. Chem Pharm Bull 1984;32:733-8
5. Zhang FM, Yao XJ, Tian X, Tu YQ. Synthesis and biological evaluation of new 4beta-5-Fu-substituted 4'-Demethylepipodophyllotoxin derivatives. Molecules 2006;11:849-57
6. Zhang CX, Zhang ZB, Chen HM, et al. Synthesis of 1,2- and 1,3- cyclic phospholipid conjugates of N1-(2- Furanidyl)-N3-(2-hydroxyethyl)-5- fluorouracil. Heteroatom Chem 1998;9:295-8
7. Jung EY, Chung ID, Lee NJ, et al. Syntheses, antitumor activities, and antiangiogenesis of a monomer and its medium molecular weight polymers: maleimidoethanoyl-5-fluorouracil and its polymers. J Polym Sci Part A Polym Chem 2000;38:1247-56
8. Lee JS, Jung YJ, Kim YM. Synthesis and evaluation of N-acyl-2-(5- fluorouracil-1- yl)- D,L- glycine as a colon-specific prodrug of 5-lluorouracil. J Pharm Sci 2001;90:1787-94
9. Marchal JA, Nunez MC, Aranega A, et al. Acyclonucleosides, modified seco-nucleosides, and salicyl- or catechol-derived acyclic 5-fluorouracil O, N-acetals: antiproliferative activities, cellular differentiation and apoptosis. Curr Med Chem 2009;16:1166-83
10. Malet-Martino M, Jolimaitre P, Martino R. The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents 2002;2:267-310
11. Zhang N, Yin Y, Xu SJ, Chen WS. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules 2008;13:1551-69
12. Hardman JG, Limbird LE, Gilman AG, et al. The pharmacological basis of therapeutics. 10th edition. McGraw-Hill; New York: 2001
13. Grem JL, Nguyen D, Monahan BP, et al. Sequence-dependent antagonism between fluorouracil and paclitaxel in human breast cancer cells. Biochem Pharmacol 1999;58:477-86
14. Tokunaga E, Oda S, Fukushima M, et al. Differential growth inhibition by 5-fluorouracil in human colorectal carcinoma cell lines. Eur J Cancer 2000;36:1998-2006
15. Marchal JA, Boulaiz H, Suarez I, et al. Growth inhibition, G(1)-arrest, and apoptosis in MCF-7 human breast cancer cells by novel highly lipophilic 5-fluorouracil derivatives. Invest New Drugs 2004;22:379-89
16. Wyatt MD, Wilson DM III. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci 2009;66:788-99
17. Backus HH, Dukers DF, van Groeningen CJ, et al. 5-fluorouracil induced Fas upregulation associated with apoptosis in liver metastases of colorectal cancer patients. Ann Oncol 2001;12:209-16
18. Yukimoto K, Nakata B, Mugurama K, et al. Apoptosis and thymidylate synthase inductions by 5-fluorouracil in gastric cancer cells with or without p53 mutation. Int J Oncol 2001;19:373-8
19. Yoshikawa R, Kusonoki M, Yanagui H, et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res 2001;61:1029-37
20. Garcia MA, Carrasco E, Aguilera M, et al. The chemotherapeutic drug 5-fluorouracil promotes PKR-mediated apoptosis in a p53- independent manner in colonand breast cancer cells. PLoS One 2011;6:e23887
21. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 2003;3:330-8
22. Thomas DM, Zalcberg JR. 5-fluorouracil: a pharmacological paradigm in the use of cytotoxics. Clin Exp Pharmacol Physiol 1998;25:887-95
23. Showalter SL, Showalter TN, Witkiewicz A, et al. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther 2008;7:986-94
24. Diasio RB, Harris BE. Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 1989;16:215-37
25. Grem JL, Yee LK, Venzon DJ, et al. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells. Cancer Chemother Pharmacol 1997;40:117-25
26. Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5-fluorouracil chemotherapy. Clin Pharmacol Ther 1995;58:512-22
27. Eng C, Kindler HL, Schilsky RL. Oral fluoropyrimidine treatment of colorectal cancer. Clin Colorectal Cancer 2001;1:95-103
28. van Kuilenburg AB. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004;40:939-50
29. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised? Clin Pharmacokinet 2006;45:567-92
30. Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer 2005;5:447-58
31. Grem JL. 5-Fluorouracil: forty-plus and still ticking. A review of its preclinical and clinical development. Invest New Drugs 2000;18:299-313
32. de Bono JS, Twelves CJ. The oral fluorinated pyrimidines. Invest New Drugs 2001;19:41-59
33. Drewinko B, Yang LY. Cellular basis for the inefficacy of 5FU in human colon carcinoma. Cancer Treat Rep 1985;69:1391-8
34. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975;36:123-8
35. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32
36. Gamelin EC, Danquechin-Dorval EM, Dumesnil YF, et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 1996;77:441-51
37. Saif NW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-Fluorouracil: a rational pproach to improving therapeutic outcomes J Natl Cancer Inst. 2009;101:1543-52
38. Petty RD, Cassidy J. Novel fluoropyrimidines: improving the efficacy and tolerability of cytotoxic therapy. Cancer Drug Targets. 2004;4:191-04
39. Cooke R, Bright MJ, Coleman KP, et al. Fluorine in medicinal chemistry:a review of anti-cancer agents. J Fluor Chem 2001;5:383-6
40. Milano G, Schellens JHM. Pyrimidine antimetabolites. In: Schellens JHM, McLeod HL, Newell DR, editors. Cancer Clinical Pharmacology. University Press; Oxford: 2005
41. Townsend E, Robert A. Synthesis of 1-(tetrahydro-2-furanyl)-5- fluorouracil (Ftorafur) via direct fluorination. US3682917; 1976
42. Au JL, Sadee W. The pharmacology of ftorafur (R, S-1-(tetrahydro- 2-furanyl)- 5-fluorouracil. Recent Results Cancer Res 1981;76:100-14
43. Komastsu T, Yamazaki H, Shimada N. Roles of cytochromes P-450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos 2000;28:1457-63
44. Cook AF. Fluorinated pyrimidine nucleoside with cytostatic activity. US 4071680; 1978
45. Wu WK, Lee CW, Cho CH, et al. MicroRNAdysregulation in gastriccancer: a new player enters the game. Oncogene 2010;29:5761-71
46. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol 2010;11:136-46
47. Ikeda N, Shimada Y, Atsushi O, et al. A Phase II study of doxifluridine in elderly patients with advanced gastric cancer: the Japan Clinical Oncology Group Study (JCOG 9410). Jpn J Clin Oncol 2002;32:90-4
48. Nukaya H, Kajino S, Tokuda H, et al. Bi-weekly docetaxel and doxifluridine combination therapy in pretreated patients with unresectable and/or advanced gastric cancer. Gan To Kagaku Ryoho 2010;37:1713-17
49. Cooke JWB, Bright R, Mark J, et al. Process research and development of a dihydropyrimidine dehydrogenase inactivator: large-scale preparation of eniluracil using a Sonogashira coupling. Org Process Res Dev 2001;5:383-6
50. Schilsky RL, Kindler HL. Eniluracil: an irreversible inhibitor of dihydropyrimidine dehydrogenase. Expert Opin Investig Drugs 2000;91:635-49
51. Czito BG, Hong TJ, Cohen DP. A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon. Int J Radiat Oncol Biol Phys 2004;58:779-85
52. Isanbor C, Hagan D. A review of anti-cancer agents. J Fluorine Chem 2006;127:303-19
53. Cerqueira P, Fernandes M, Ramos J. Understanding ribonucleotide reductase inactivation by gemcitabine. Chem Eur J 2007;3:8507-15
54. Hodge LS, Taub ME, Tracy TS. Effect of its deaminated metabolite, 2¢,2¢-difluorodeoxyuridine, on the transport and toxicity of gemcitabine in HeLa cells. Biochem Pharmacol 2011;81:950-6
55. Pourquier P, Gioffre C, Kohlhage G, et al. Gemcitabine (2¢,2¢-Difluoro-2¢- Deoxycytidine), an antimetabolite that oisons topoisomerase I. Clin. Cancer Res 2002;8:2499-04
56. Tam JC, Medford NY, Mei Q, et al. Novel polysacchocride prodrug of 5-fluorouracil (5-FU) with enhanced target specificity for colon rectal cancer and its preparation methods. US 0085871; 2008
57. Huang J, Gao CS, Mei XG. New type of colon targeting drug delivery system. Foreign Med Sciences 2002;29:306-8
58. Schoeppner HL, Raz A, Ho SB. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1995;75(12):2818-26
59. Yoshii T, Fukumori T, Honjo Y, et al. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arresto. J Biol Chem 2002;277:6852-7
60. Byrd JC, Bresalier RS. Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 2004;23:77-9
61. Campos J, Espinosa A, Gallo MA, et al. 2,3-dihidro-5H-1-4 benzodiheroepin- 3IL) purinas con actividad antitumoral. ES2303444B2; 2009
62. Campos J, Pineda MJ, Gomez JA, et al. 5-Fluorouracil derivatives 1. Aacyclonucleosides through a tin (IV) chloride-mediated regiospecific ring opening of alkoxy-1,4-diheteroepanes. Tetrahedron 1996;52:8907-24
63. Campos J, Gomez JA, Trujillo MA, et al. Diheterocyclanes as synthons for the preparation of novel series of nucleoside and acyclonucleoside analogues. Farmacol 1997;52:263-9
64. Saniger E, Campos JM, Entrena A, et al. Medium benzene-fused oxacycles with the 5-fluorouracil moiety: synthesis, antiproliferative activities and apoptosis induction in breast cancer cells. Tetrahedron 2003;59:5457-67
65. Saniger E, Campos JM, Entrena A, et al. Neighbouring-group participation as the key step in the reactivity of acyclic and cyclic salicyl-derived O,O-acetals with 5-fluorouracil. Antiproliferative activity, cell cycle dysregulation and apoptotic induction of new O,N-acetals against breast cancer cells. Tetrahedron 2003;59:8017-26
66. Espinosa A, Marchal JA, Aranega A, et al. Antitumoral properties of benzannelated seven-membered 5-fluorouracil derivatives and related open analogues. Molecular markers for apoptosis and cell cycle dysregulation. Il Farmaco 2005;60:91-7
67. Malet-Martino M, Martino R. Clinical studies of three oral prodrugs of 5-Fluorouracil (Capecitabine, UFT, S-1): a review. Oncologist 2002;7:288-323
68. Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorourd dacil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol 1989;7:1419-26
69. Buroker TR, O'Connell MJ, Wieand HS, et al. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;12:14-20
70. Gray BN. Combination therapy of oxaliplatin and radioactively doped particles treating cancer. US0115424Al; 2006
71. Jeon EK, Hong SH, Kim TH, et al. Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer. Cancer Res Treat 2011;43(3):148-53
72. Gamelin E, Bois M, Juigne A. Individual 5 fluorouracile dose optimization in folfiri treatment. US0177092A1; 2011
73. Fakih MG, Groman A, McMahon J, et al. A randomized phase II study of two doses of vorinostat in combination with 5-FU/LV in patients with refractory colorectal cancer. Cancer Chemother Pharmacol 2011: published online 22 October 2011, doi:10.1007/s00280-011-1762-1
74. Silvestris N, Maiello E, De Vita F, et al. Update on capecitabine alone and in combination regimens in colorectal cancer patients. Cancer Treat Rev 2010;36(Suppl 3):S46-55
75. Bachelot T, Bajard A, Ray-Coquard I, et al. Final results of ERASME-4: a randomized trial of first-line docetaxel plus either capecitabine or epirubicin for metastatic breast cancer. Oncology 2011;80(3-4):262-8
76. Xie DR, Yang Q, Chen DL, et al. Gemcitabine-based cytotoxic doublets chemotherapy for advanced pancreatic cancer: updated subgroup meta-analyses of overall survival. Jpn J Clin Oncol 2010;40(5):432-41
77. Amarantidis K, Xenidis N, Chelis L, et al. Docetaxel plus oxaliplatin in combination with capecitabine as first-line treatment for advanced gastric cancer. Oncology 2011;80:359-65
78. Resch G, De Vries A, Ofner D, et al. Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer - A two stage phase II clinical trial. Radiother Oncol 2012;102:10-13
79. Pharmacia Italia. A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent. EP050130; 2004
80. Pharmacia Italia. A combined therapy comprising an indolopyrrolocarbazole derivative and another antitumor agent. WO073719; 2004
81. Fujimoto-Ouchi K, Sekiguchi F, Tanaka Y, Yanagisawa M. Combinedtreatment with capecitabine and an epidermal growth factor receptor kinase inhibitor. US0178387Al; 2006
82. Fujii S, Kitano S, Ikenaka K, et al. Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5- fluorouracil and level of 5-fluorouracil in rodents. Gann 1979;70:209-14
83. Hoff PM. The tegafur-based dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines, UFT/ leucovorin (ORZEL™) and S-1: a review of their clinical development and therapeutic potential. Invest New Drugs 2000;18:331-42
84. Munoz R, Man S, Shaked Y, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-91
85. Lin BR, Lai HS, Chang TC, et al. Long-term survival results of surgery alone versus surgery plus UFT (Uracil and Tegafur)-based adjuvant therapy in patients with stage II colon cancer. J Gastrointest Surg 2011;15:2239-45
86. Mitsuo O F, Hiromi WS, Harubumi K, et al.Postoperative adjuvant chemotherapy with UFT. US0245478A119; 2005
87. Ota K, Taguchi T, Kimura K. Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 1988;22:333-8
88. Chazard M. Oral dosage form for administration of the combination of tegafur uracil folinic acid and oxaliplatin and method of using the same. US006602870B2; 2003
89. Winer EP, Bunnell CA, Ressler J, et al. Method for treating tumors by the administration of tegafur uracil folinic acid and cyclophosphamide. US6620816B2; 2003
90. Jafferhusen AA, Benner SE, Dugan TS, et al. Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin. US6770653B2; 2004
91. Ishihara S, Hayama T, Yamada H, et al. Benefit of tegafur-uracil and leucovorin in chemoradiotherapy for rectal cancer. Hepatogastroenterology 2011;58:756-62
92. Cellier P, Leduc B, Martin L, et al. Phase II study of preoperative radiation plus concurrent daily tegafur-uracil (UFT) with leucovorin for locally advanced rectal cancer. BMC Cancer 2011;11:98
93. Shirasaka T, Fukushima M, Ohshimo H, et al. Compositions, methods and kits for potentiating antitumor effect and for treating tumor. US5525603; 1996
94. Peters GJ, Noordhuis P, Van Kuilenburg AB, et al. Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4- dihydroxypyridine (molar ratio 1 : 0.4 : 1) in patients with solid tumors. Cancer Chemother Pharmacol 2003;52:1-12
95. Ichikawa W, Sasaki Y. Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients. Int J Clin Oncol 2008;13:206-11
96. Konno H, Tanaka T, Baba M, et al. Therapeutic effect of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) on liver metastasis of xenotransplanted human colon carcinoma. Jpn J Cancer Res 1999;90:448-53
97. Nishimura G, Yanoma S, Mizuno H, et al. Therapeutic effect of 1 M tegafur- 0.4 M 5-chloro-2,4-dihydroxypyridine- 1 M potassium oxonate (S-1) on head and neck squamous carcinoma cells. Cancer Lett 2000;159:1-7
98. Takechi T, Nakano K, Uchida J, et al. Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 1997;39:205-11
99. Nomura N, Nomura K, Takeshi T, et al. Method for reducing gastrointestinal toxicity due to the administration of tegafur. US0166427A1; 2008
100. Araki H, Fukushima M, Kamiyama Y, et al. Effect of consecutive lower-dose cisplatin in enhancement of 5-fluorouracil cytotoxicity in experimental tumor cells in vivo. Cancer Lett 2000;160:185-91
101. Taguchi T, Inuyama Y, Kanamaru R, et al. Phase I study of S-1. S-1 Study Group. Gan To Kagaku Ryoho 1997;24:2253-64; Japanese
102. van Groeningen CJ, Peters GJ, Schornagel JH, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol 2000;18:2772-9
103. Meropol NJ, Leishman CG, Yeslow G, et al. Phase I and pharmacokinetic study of single daily oral administration of S-1. Proc Am Soc Clin Oncol 2001;20:361a
104. Horikoshi N, Mitachi Y, Sakata Y, et al. S-1, new oral fluoropyrimidine is very active in patients with advanced gastric ancer (early phase II study). Proc Am Soc Clin Oncol 1996;15:466a
105. Kawahara M, Furuse K, Segawa Y, et al. Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 2001;85:939-43
106. Pasini F, Fraccon AP, DE Manzoni G. The role of chemotherapy in metastatic gastric cancer. Anticancer Res 2011;31(10):3543-54
107. Yamao T, Shimada Y, Kondo H, et al. Clinical trial of continuous infusion of 5-Fluorouracil using an ambulatory pump for metastatic colorectal cancer. Jpn J Oncol 1995;25:46-50
108. Tanaka F, Fukuse T, Wada H, Fukushima M. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic agents. Curr Pharm Biotechnol 2000;1:137-64
109. Grem JL. Fluorinated pyrimidines. In: Chabner BA, Collins JM, editors. Cancer Chemotherapy: Principles and Practice. J. B. Lippincott Company; Philadelphia, PA: 1990. p. 180-224
110. Yamamoto S, Kotani H, Kaneda Y. Medicinal preparation having chemotherapeutic encapsulated therein. WO039406; 2004
111. Yamamoto S, Kotani I, Kaneda Y. Chemotherapeutic agent-incorporated pharmaceutical preparation. US7427395; 2008
112. Gupte A, Ciftci K. Formulation and characterization of Paclitaxel, 5-FU and Paclitaxel + 5-FU microspheres. Int J Pharm 2004;276:93-106
113. Fu Y-J, Shyu SS, Su F-H, et al. Development of biodegradable co-poly (D,L-lactic/glycolic acid) microspheres for the controlled release of 5-FU by the spray drying method. Colloids Surf B Biointerfaces 2002;25:269-79
114. Haznedar S, Dortunc B. Preparation and in vitro evaluation of Eudragit microspheres containing acetazolamide. Int J Pharm 2004;269:131-40
115. Boisdron-Celle M, Menei P, Benoit JP. Praparation of biodegradable 5-fluorouracil-loaded microspheres. J Pharm Pharmacol 1995;47:108-14
116. Faisant N, Benoit J-P,Menei P. Use of biodegradable microspheres for the delivery of a anticancer agent for the treatment of lioblastoma.WO69413; 2000
117. Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002;1587:194-205
118. Ciccolini J, Cuq P, Evrard A, et al. Combination of thymidine phosphorylase gene transfer and deoxyinosine treatment greatly enhances 5-fluorouracil antitumor activity in vitro and in vivo. Mol Cancer Ther 2001;1:133-9
119. De Bruin M, van Capel T, Smid K, et al. Role of platelet derived endothelial cell growth factor/thymidine phosphorylase in fluoropyrimidine sensitivity and potential role of deoxyribose-1 -phosphate. Nucleosides Nucleotides Nucleic Acids 2004;23:1485-90
120. Fanciullino R, Giacometti S, Aubert C, et al. Development of stealth liposome formulation of 2'-deoxyinosine as 5-fluorouracil modulator: in vitro and in vivo study. Pharm Res 2005;22:2051-7
121. Ciccolini J, Fanciullino R. Liposomal formulations for treating cancer. WO034148A1; 2009
122. Torchilin VP. Passive and active drug targeting: drug delivery to tumors as an example. Handb Exp Pharmacol 2010;197:3-53
123. Mikhail AS, Allen C. Block copolymer micelles for delivery of cancer therapy: transport at the whole body, tissue and cellular levels. J Control Release 2009;138:214-23
124. Fang J, Sawa T, Akaike T, Maeda H. Tumor-targeted delivery of polyethylene glycol-conjugated D-amino acid oxidase for antitumor therapy via enzymatic generation of hydrogen peroxide. Cancer Res 2002;62:3138-43
125. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target 2007;15:457-64
126. Huober J, Fett W, Nusch A, et al. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer 2010;10:2
127. O'Brien ME. Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer. Anticancer Drugs 2008;19:1-7
128. Chen J. Two-step targeted tumor therapy with prodrug encapsulated in nanocarrier. US0217363A1; 2011
129. Yadav AK, Agarwal A, Jain S, et al. Chondroitin sulphate decorated nanoparticulate carriers of 5-fluorouracil: development and in vitro characterization. J Biomed Nanotechnol 2010;6:340-50
130. Lai LF, Guo HX. Preparation of new 5-fluorouracil-loaded zein nanoparticles for liver targeting. Int J Pharm 2011;404:317-23
131. Danenberg FV. Pharmacogenomics of thymidylate synthase in cancer treatment. Front Biosci 2004;9:2484-94
132. Im YH, Park YH. Efficacy comparison study of combination regimens to treat advanced esophageal squamous cell carcinoma (XP versus XT). ClinicalTrials.gov identifier: NCT00816634
133. Kang YK. Capecitabine versus S-1 in elderly advanced gastric cancer (AGC): Randomized trial. ClinicalTrials.gov identifier: NCT00278863
134. Kim BS. RCT With adjuvant mistletoe treatment in gastric cancer patients. ClinicalTrials.gov identifier: NCT01401075
135. Steiner M, Seule M, Steiner B, et al. 5-Fluorouracil/irinotecan induced lethal toxicity as a result of a combined pharmacogenetic syndrome: report of a case. J Clin Pathol 2005;58:553-5
136. Marchal JA, Rodriguez-Serrano F, Caba O, et al. Antiproliferative activity, cell-cycle dysregulation, and cellular differentiation: salicyl- and catecholderived acyclic 5-fluorouracil O,N-acetals against breast cancer cells. Chem Med Chem 2007;2:1814-21